BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld
Home
» Genentech, XOMA Come Through With Strong Phase III Raptiva Data
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Genentech, XOMA Come Through With Strong Phase III Raptiva Data
Sep. 18, 2002
By
Brady Huggett
No Comments
When trying to get a drug approved, biotechnology companies must provide the FDA with data - data showing that a drug is efficacious, that it works in the appropriate patient and that it is safe, among other things. (BioWorld Today)
BioWorld